113 related articles for article (PubMed ID: 36345952)
1. Immunohistochemical evaluation of forkhead box A1 and EphA5 markers in serous ovarian carcinomas, and their impact on the clinical outcome of patients.
Abouhashem N; Harb O; Elwan A; Zaitoun M; Saraya Y
Pol J Pathol; 2022; 73(2):120-133. PubMed ID: 36345952
[TBL] [Abstract][Full Text] [Related]
2. EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.
Chen X; Wang X; Wei X; Wang J
J Ovarian Res; 2016 Nov; 9(1):83. PubMed ID: 27887627
[TBL] [Abstract][Full Text] [Related]
3. High FOXA1 immunohistochemical expression level associates with mucinous histology, favorable clinico-pathological prognostic parameters and survival advantage in epithelial ovarian cancer.
Sheta H; Abd El Hafez A; Saif M; Elsergany AR; Al Emam D; Abdelrazik MM
Pathologica; 2021 Apr; 113(2):102-114. PubMed ID: 34042091
[TBL] [Abstract][Full Text] [Related]
4. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
5. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
6. The clinical significance of forkhead box protein A1 and its role in colorectal cancer.
Ma W; Jiang J; Li M; Wang H; Zhang H; He X; Huang L; Zhou Q
Mol Med Rep; 2016 Sep; 14(3):2625-31. PubMed ID: 27484093
[TBL] [Abstract][Full Text] [Related]
7. Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells.
Abe Y; Ijichi N; Ikeda K; Kayano H; Horie-Inoue K; Takeda S; Inoue S
Cancer Sci; 2012 Apr; 103(4):806-12. PubMed ID: 22313737
[TBL] [Abstract][Full Text] [Related]
8. EphB3 protein is associated with histological grade and FIGO stage in ovarian serous carcinomas.
Gao W; Zhang Q; Wang Y; Wang J; Zhang S
APMIS; 2017 Feb; 125(2):122-127. PubMed ID: 28120491
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 is expressed in ovarian mucinous neoplasms.
Karpathiou G; Venet M; Mobarki M; Forest F; Chauleur C; Peoc'h M
Pathology; 2017 Apr; 49(3):271-276. PubMed ID: 28238418
[TBL] [Abstract][Full Text] [Related]
10. Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.
Jin Y; Zou Y; Wan L; Lu M; Liu Y; Huang G; Wang J; Xi Q
Mol Med Rep; 2018 Apr; 17(4):5409-5415. PubMed ID: 29393455
[TBL] [Abstract][Full Text] [Related]
11. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
12. Expression of PH Domain Leucine-rich Repeat Protein Phosphatase, Forkhead Homeobox Type O 3a and RAD51, and their Relationships with Clinicopathologic Features and Prognosis in Ovarian Serous Adenocarcinoma.
Zhang J; Wang JC; Li YH; Wang RX; Fan XM
Chin Med J (Engl); 2017 Feb; 130(3):280-287. PubMed ID: 28139510
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
14. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
15. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
16. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
[TBL] [Abstract][Full Text] [Related]
17. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of EphA5 is associated with Fuhrman nuclear grade and pathological tumour stage in ccRCC.
Wang X; Xu H; Wu Z; Chen X; Wang J
Int J Exp Pathol; 2017 Feb; 98(1):34-39. PubMed ID: 28421649
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
20. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
[Next] [New Search]
